Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arrowhead Pharmaceuticals
Biotech
Sarepta shares safety update on DM1 RNA med
A drug safety group has delivered a positive review for an investigational siRNA being studied in a phase 1/2 trial for type 1 myotonic dystrophy.
Gabrielle Masson
Nov 24, 2025 4:00pm
Arrowhead sues Ionis over patent dispute for Tryngolza rival
Sep 11, 2025 11:33am
Novartis aims at alpha-synuclein again with $2.2B Arrowhead deal
Sep 2, 2025 9:55am
Sarepta sells 9M Arrowhead shares for $174M cash
Aug 13, 2025 5:44pm
Sanofi pens $395M China pact for Arrowhead metabolic med
Aug 1, 2025 7:21am
Arrowhead meets $100M milestone, awaits Sarepta payment
Jul 28, 2025 3:10pm
